HK Stock MarketDetailed Quotes

09995 REMEGEN

Watchlist
  • 19.300
  • +2.460+14.61%
Market Closed Nov 1 16:08 CST
10.51BMarket Cap-6103P/E (TTM)

About REMEGEN Company

The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.

Company Profile

Symbol09995
Company NameREMEGEN
ISINCNE1000048G6
Listing DateNov 9, 2020
Issue Price52.10
Shares Offered76.54M share(s)
FoundedJul 4, 2008
Registered AddressChina
Chairmanweidong wang
Secretaryshaojingtanbairu tong
Audit InstitutionErnst & Young
Company CategoryMainland registration of Mainland Individuals control
Registered OfficeNo. 58, Beijing Middle Road, Yantai Development Zone, Yantai Area, Shandong Pilot Free Trade Zone, China
Head Office and Principal Place of Business40th Floor, Dah Sing Financial Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees3497
MarketHong Kong motherboard
Phone0535-3573685
Fax0535-6113517
Emailrcsw@remegen.cn
Websitehttp://www.remegen.cn/
BusinessResearch, develop, produce and sell pharmaceutical products and diagnostic reagent products, and carry out technical services, technology transfer, import and export of goods or technology related to the above products and their research and development (except for the import and export of goods and technology prohibited by the country or involving administrative approval). (For projects requiring approval according to law, business activities can only be carried out after approval by relevant departments)

Company Executives

  • Name
  • Position
  • Salary
  • weidong wang
  • Chairman, Executive Director, Strategy Committee Members, Nomination Committee Members
  • --
  • jianmin fang
  • CEOs, Executive Director, Chief Scientific Officer, Chairman of the Strategy Committee, Authorized Representative
  • --
  • ruyi he
  • Executive Director, Clinical Research Supervisor, Chief Medical Officer, Strategy Committee Members
  • --
  • jian lin
  • Executive Director, Remuneration Committee Members
  • --
  • liqiang wang
  • Non-executive Directors, Strategy Committee Members, Audit Committee Members
  • --
  • xiaodi su
  • Non-executive Directors, Strategy Committee Members
  • --
  • yunjin chen
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members
  • 300.00K
  • xianjing hao
  • Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members, Remuneration Committee Members
  • --
  • lan ma
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Strategy Committee Members
  • --
  • guangke ren
  • Auditors
  • --
  • yupeng li
  • Auditors
  • --
  • zhuanglin li
  • Auditors
  • --
  • qingkai wen
  • Board Secretary
  • --
  • shaojing tong
  • Chief Financial Officer, Joint Company Secretary
  • --
  • bairu tan
  • Joint Company Secretary, Authorized Representative
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data